Skip to main content
. 2012 May 14;4(2):252–275. doi: 10.3390/pharmaceutics4020252

Scheme 4.

Scheme 4

Hypothetical ways that are taken advantage of the breakdown of the blood-ocular barrier for systemically administered nanosystems.